Frespaciguat

Merck is running INSIGNIA-PH-COPD (NCT05612035), a Phase 2 trial of frespaciguat (MK-5475), an inhaled soluble guanylate cyclase stimulator, in patients with pulmonary hypertension caused by chronic obstructive pulmonary disease [1]. PH-COPD has no approved therapies and median survival once diagnosed is short, generally under three years in published series. The trial enrolled 129 patients and is now in follow-up, with 6-minute walk distance (6MWD) at week 24 as the primary endpoint. A parallel Phase 2 program in pulmonary arterial hypertension (INSIGNIA-PAH, NCT04732221) completed enrollment at n=168 with a hemodynamic primary endpoint - pulmonary vascular resistance (PVR), the standard mechanism-grade measure of how hard the right heart works to push blood through the lungs [2]. Frespaciguat is the same drug class as Bayer's approved riociguat (Adempas) and Merck/Bayer's vericiguat (Verquvo), but delivered by inhalation rather than orally - a deliberate design choice to engage the pulmonary vasculature while limiting systemic hypotension. For Merck this is a category bet, not a near-term commercial lever; at ~$65B in annual revenue the asset has to define a new indication to matter, and PH-COPD is the most ambitious version of that thesis [7].

Frespaciguat is a novel compound, never approved for any indication anywhere. INSIGNIA-PH-COPD (NCT05612035) is the lead Phase 2, listed as active-not-recruiting at n=129 with a 24-week primary endpoint [1]. The parallel pulmonary arterial hypertension Phase 2/3 (INSIGNIA-PAH, NCT04732221, n=168) is listed as completed for its Phase 2 cohort [2]. Earlier work includes a Phase 1 single-dose PVR study (NCT03744637, n=25) and a Phase 1 PH-COPD safety study (NCT04370873, n=22) [3]. Detailed efficacy and tolerability results from the Phase 1 PH-COPD study have not been published in peer review, so the dose-selection rationale carried into Phase 2 is not externally auditable. Two pharmacology papers landed in the last twelve months: a radiolabeled mass-balance and PK study in J Clin Pharmacol in 2025 [4], and a single-dose hemodynamic interaction study with sildenafil reported in early 2026 [5] - the PMID for that second paper could not be verified at write time and should be confirmed against PubMed before citation. No FDA Breakthrough Therapy, Fast Track, Orphan Drug, or RMAT (Regenerative Medicine Advanced Therapy) designations are public. Merck has not given calendar guidance for either Phase 2 readout or disclosed a Phase 3 PH-COPD plan, so the next observable catalyst is whichever INSIGNIA cohort reports first. INSIGNIA-PAH (12-week primary, enrollment completed 2023-2024) data should exist now and, to our knowledge, have not been presented at a major cardiopulmonary meeting through mid-2026 - making the readout effectively overdue and a near-term watch item. Even in the bull case, a regulatory filing in PH-COPD would not arrive before late 2027.

Soluble guanylate cyclase (sGC) is the enzyme inside vascular smooth muscle cells that makes cGMP, a second messenger that tells blood vessels to relax. The normal trigger is nitric oxide (NO) released by healthy endothelium. In pulmonary hypertension, especially the kind driven by COPD, chronic hypoxia and oxidative damage starve sGC of working NO signaling, so the pulmonary arteries stay constricted and remodel. sGC stimulators bind a separate allosteric site on the enzyme and increase cGMP production even when NO signaling is low. The mechanism is well-validated. Bayer's riociguat (Adempas) is approved for both PAH and chronic thromboembolic pulmonary hypertension (CTEPH) on exactly this biology [6], generating several hundred million dollars in annual sales. Merck/Bayer's vericiguat (Verquvo) is approved for worsening heart failure on the same target family. The unknown for frespaciguat is delivery. It is inhaled rather than oral. Inhaled dosing concentrates drug at the pulmonary vasculature and - by the thesis - avoids the systemic hypotension that has limited oral riociguat in COPD patients, who are often already on tiotropium, LABAs, supplemental oxygen, and sometimes systemic vasodilators. The risk is the mirror image: by reaching only better-ventilated alveoli, the inhaled formulation may not deliver the same magnitude of PVR reduction as oral riociguat. The INSIGNIA-PAH Phase 2 PVR data will resolve this directly.

INSIGNIA-PH-COPD (NCT05612035) is a Phase 2, placebo-controlled study in adults with pulmonary hypertension confirmed by right heart catheterization in the context of COPD [1]. Enrollment is closed at n=129 and the trial is in follow-up. The primary endpoint is mean change from baseline in 6MWD at week 24, the same functional anchor that supported riociguat's PAH approval. The design has a known weakness for the COPD setting: 6MWD is confounded by exacerbations and dyspnea unrelated to pulmonary hemodynamics, both of which are common in this population. A hemodynamic primary (PVR) would have given a cleaner mechanism readout. The PAH-focused INSIGNIA-PAH (NCT04732221) did use PVR as primary at 12 weeks in a Phase 2 cohort of n=168, with a planned Phase 3 cohort to follow [2]. Strategically, PAH is the mechanism proof and PH-COPD is the indication bet. The comparator is placebo on top of background COPD therapy, which is the correct choice given there is no approved PH-COPD drug. The 129-patient enrollment is modest by Phase 3 standards but reasonable for a Phase 2 looking for a 25-30 meter functional signal at week 24.

Most drugs tested in clinical trials never make it to approval, and this drug is no different - our model estimates a 9% chance it is eventually approved. The starting point is the historical approval rate for Phase 2 drugs in this area, around 27%, which the model then adjusts based on ten specific facts about the trial and its sponsor. The estimate is pulled up by the sponsor's strong track record of approvals, but pulled down by weak earlier-phase results, heavy blinding, and a randomized trial design. The remaining factors are typical for this stage and leave the estimate close to where it started.

Efficacy risk first, because it is the largest. PH-COPD is the indication where pulmonary vasodilators have repeatedly failed. Sildenafil - a PDE5 inhibitor that operates on the same cGMP axis downstream of sGC - has shown no functional benefit and possible harm in PH-COPD trials, with the canonical concern being V/Q mismatch: dilating vessels in poorly ventilated lung regions diverts blood away from well-ventilated regions and worsens hypoxemia [9]. Inhaled delivery is supposed to mitigate this by depositing drug preferentially in better-ventilated alveoli, but that is a pharmacology hope, not a proven property in humans. If the PAH Phase 2 PVR signal is weak, the COPD program almost certainly fails on efficacy. Safety risk: on-target systemic hypotension is the predictable problem for any sGC stimulator. Riociguat is contraindicated with PDE5 inhibitors for exactly this reason. The fact that Merck ran and reported a sildenafil-frespaciguat interaction study in early 2026 [5] signals concern about co-administration, which matters because PH patients are often on PDE5 inhibitors as background therapy. Execution risk: the 6MWD endpoint is sensitive to COPD exacerbations, and dropouts for non-PH reasons could blunt a real signal. Commercial risk: PH-COPD is a narrow specialist population (roughly 20-30K diagnosed in the US), reimbursement for inhaled specialty therapies is harder than for oral, and Merck's revenue base means the internal threshold for program continuation is high. Riociguat itself generates only mid-hundreds of millions; even a clean approval would not move Merck's earnings story.

Worth watching, but the signal node is INSIGNIA-PAH (NCT04732221), not INSIGNIA-PH-COPD. PAH data tells us whether inhaled sGC stimulation engages the target at all - PVR is a mechanism-grade endpoint and the PAH patient population is cleaner than PH-COPD. If that readout shows a clinically meaningful PVR reduction without dose-limiting hypotension or V/Q-mismatch hypoxemia, frespaciguat becomes a real platform asset for Merck, and PH-COPD becomes the upside indication on top of a real PAH commercial. If PAH is negative or marginal, PH-COPD almost certainly fails. Check back when Merck reports the INSIGNIA-PAH Phase 2 cohort data - likely at AHA (American Heart Association), ATS (American Thoracic Society), or ERS (European Respiratory Society) annual meetings, or via an 8-K (the SEC filing public companies use to disclose material events). With the 12-week primary and enrollment completed in 2023-2024, the data are effectively overdue; absence of a 2026 presentation slot would itself be a soft negative signal. The PH-COPD primary readout will not surface until mid-to-late 2026 at the earliest given the week-24 endpoint and active-not-recruiting status. Commercial framing: at a PAH-comparable list price (~$100K/year) and 20% penetration of a 25K diagnosed US population, peak US revenue is on the order of $500M - enough to justify the program but not needle-moving for Merck at $65B in revenue [7]. Strategic context: riociguat is Bayer's, vericiguat is Merck/Bayer co-developed, and frespaciguat (MK-5475) appears to be Merck-independent based on publicly available development history; Bayer's franchise exposure is therefore competitive rather than co-development, though no public partnering arrangement on frespaciguat has been disclosed. Composition-of-matter patent timing on frespaciguat is not publicly mapped in this writeup; based on typical small-molecule timelines, primary patent protection likely extends into the mid-2030s with potential Hatch-Waxman extension after approval, but this needs confirmation from the Orange Book once an NDA is filed. Track INSIGNIA-PAH for the science; track INSIGNIA-PH-COPD for the indication-creation story.